Translational regulation as a novel mechanism for the development of cellular drug resistance

J C Schmitz; J Liu; X Lin; T M Chen; W Yan; N Tai; A Gollerkeri; E Chu

doi:10.1023/a:1013100306315

Translational regulation as a novel mechanism for the development of cellular drug resistance

Cancer Metastasis Rev. 2001;20(1-2):33-41. doi: 10.1023/a:1013100306315.

Authors

J C Schmitz¹, J Liu, X Lin, T M Chen, W Yan, N Tai, A Gollerkeri, E Chu

Affiliation

¹ Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA CT Cancer Center, VA CT Healthcare System, New Haven 06516, USA.

PMID: 11831645
DOI: 10.1023/a:1013100306315

Abstract

Cellular drug resistance is one of the principal obstacles to the clinical efficacy of cancer chemotherapy. In this review, we describe the potential role for translational regulation as a novel mechanism for modulating chemosensitivity. The evidence for the translational control of thymidylate synthase, dihydrofolate reductase, and p53 will be presented, as will experimental data showing how disruptions in this important regulatory process can lead to the rapid emergence of cellular drug resistance.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm*
Gene Expression Regulation, Enzymologic / physiology*
Humans
Neoplasms / drug therapy
Neoplasms / enzymology*
Protein Biosynthesis
Tetrahydrofolate Dehydrogenase / genetics*
Tetrahydrofolate Dehydrogenase / metabolism
Thymidylate Synthase / genetics*
Thymidylate Synthase / metabolism
Tumor Suppressor Protein p53 / genetics*
Tumor Suppressor Protein p53 / metabolism

Substances

Antineoplastic Agents
Tumor Suppressor Protein p53
Tetrahydrofolate Dehydrogenase
Thymidylate Synthase

Abstract

Publication types

MeSH terms

Substances

Grants and funding